- 1、本文档共38页,可阅读全部内容。
- 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
BIOMARKERS FOR MANAGEMENT OF EPITHELIAL 管理上皮细胞标志物
FRONTIERS IN TUMOR MARKERS Robert C. Bast, Jr., M.D. U.T. M.D. Anderson Cancer Center October 16, 2006 FRONTIERS IN TUMOR MARKERS:CA 125 FOR ACCELERATING DRUG EVALUATION IN OVARIAN CANCER THE CHALLENGE OF TARGETED DRUG DEVELOPMENT More than 400 New Drugs are Being Developed for Clinical Trials Many Targeted Drugs will be Effective Only in Combination Less than 4% of Cancer Patients Enter Clinical Trials Less than Half of Ovarian Cancer Patients meet RECIST Criteria Many Targeted Drugs will be Cytostatic CA 125 TO ACCELERATE PHASE II CLINICAL TRIALS Surrogate Marker for Response in Phase II Trials - A 50% and 75% Decrease in CA125 has correlated with Response Rates in 19 Phase II Trials of 14 Different Cytotoxic Drugs with 1000 Patients (Rustin, et al) - Use of CA125 could Double Accrual - Discontinue Trials with Poor Response - Expand Accrual to achieve RECIST Criteria Selection of Active Drugs in Phase II Trials for Ovarian Cancer According to CA 125 Response Rates Paclitaxel Platinum based Docetaxel Rhizoxin Etoposide Tallimustine Fosquidone Tomudex Gemcitabine Topotecan Isotretinoin/Calcitriol Oxaliplatin Altretamine CA 125 TO ACCELERATE PHASE III CLINICAL TRIALS CA 125 as an Endpoint for Time to Progression in Phase III Trials - Rise 2-fold above Normal or above Nadir - 84-94% Sensitive and 98% Specific - 80% precede or coincide with RECIST Combine with RECIST Criteria - RECIST takes Precedence - CA125 must be at the Same Time Points in Both Arms - Shorten Duration of Trials Comparison of CA-125 and Standard Definitions of Progression in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide (Rustin et al 2006) CA 125 TO EVALUATE NOVEL CYTOSTATIC DRUGS Monitor Response to New Cytostatic Drugs - Many Targeted Therapies are Cytostatic and Stabilize Disease - Effective Drugs could arrest A Ris
您可能关注的文档
- 4390.电子商务论文基于Web酒店预订系统设计与实现.doc
- 43立体图形表面展开图第一节.ppt
- 4 生命延续—繁殖与遗传.ppt
- 442.跨国公司进入对我国经济影响.doc
- 443.论无线局域网组网技术.doc
- 452线段计算.ppt
- 4373.基于ARM变速箱参数测控系统设计.doc
- 4444.煤与瓦斯突出防逆风装置探讨.doc
- 41园林植物与园林中其他要素配置.ppt
- 40幅有趣图片,可以考察智商和情商.ppt
- 2024至2030年中国羚羊角类饮片行业深度调查与前景预测分析报告.docx
- 重庆市面向中国农业大学定向选调2024届大学毕业生2024年国家公务员考试考试大纲历年真题14笔试历.docx
- 重庆市面向西北工业大学定向选调2024届大学毕业生00笔试历年典型考题及解题思路附答案详解.docx
- 中国不动杆菌感染治疗药行业市场现状分析及竞争格局与投资发展研究报告2024-2029版.docx
- 2024至2030年全球与中国ETL软件市场现状及未来发展趋势.docx
- 初中八年级(初二)生物下册期末考试1含答案解析.docx
- 干簧式继电器项目申请报告.docx
- 2024至2030年中国左氧氟沙星片行业深度调查与前景预测分析报告.docx
- 菜籽项目申请报告.docx
- 2024至2030年中国八角钢行业深度调查与前景预测分析报告.docx
最近下载
- 2023首席质量官真题2.pdf VIP
- 山西美盛物资贸易有限公司邓家庄煤矿机械化升级改造可行性研究报告.doc
- 思科网络实验室路由和交换实验指南.pdf
- 保洁服务投标文件示范文本.docx
- 《物联网技术导论与应用》黄玉兰习题答案.docx
- 《混凝土结构与砌体结构》 习题答案 习题答案 课后习题.doc VIP
- 中职学校《极限配合与技术测量基础》电子教案(含教学进度计划)(配套教材:劳社版中职统编)云天课件.doc
- 人教二上第4课 彩泥世界快乐多教案(表格式).doc
- 2024年国家电投集团陕西新能源有限公司渭南分公司人员招聘笔试备考题库及答案解析.docx
- 基于“互联网+”,开展立德树人——浅谈初中历史教学与思政教育的融合.docx
文档评论(0)